Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases


Experts discuss challenges in integrating gene therapy and port delivery systems early in treating common retinal diseases while emphasizing historical challenges and safety considerations.


Experts discuss the challenges and considerations associated with incorporating novel therapies like gene therapy or port delivery systems into the early treatment regimens for common retinal diseases. Seenu Hariprasad acknowledges the high bar set for future therapies due to the safety and effectiveness of currently available treatments like aflibercept 8 mg and faricimab. He suggests that a combination of tyrosine kinase inhibitors (TKIs) and gene therapy could be a powerful approach, providing a baseline therapy that can be titrated with anti-VEGF agents. David Brown, MD emphasizes the historical challenges faced with TKIs, particularly issues related to pharmacology. He raises concerns about the potential for gene therapy to cause inflammation and highlights the safety of current treatments. Diana Do, MD expresses the challenge of incorporating gene therapy or other novel therapies early when effective and safe clinic-based options are available. She suggests that these novel therapies may be more suitable for patients with high-frequency treatment needs and without additional risk factors.

This summary was AI-generated and edited for clarity.

Related Videos
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.